MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2147/tcrm.s72299

Медицинская библиотека · Therapeutics and clinical risk management · 2015

Effect of combination tablets containing amlodipine 10 mg and irbesartan 100 mg on blood pressure and cardiovascular risk factors in patients with hypertension.

Yagi Shusuke, Takashima Akira, Mitsugi Minoru, Wada Toshihiro, Hotchi Junko, Aihara Ken-Ichi, Hara Tomoya, Ishida Masayoshi, Fukuda Daiju, Ise Takayuki, Yamaguchi Koji, Tobiume Takeshi, Iwase Takashi, Yamada Hirotsugu, Soeki Takeshi, Wakatsuki Tetsuzo, Shimabukuro Michio, Akaike Masashi, Sata Masataka

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Hypertension is one of the major risk factors for cardiovascular and cerebrovascular disease and mortality. Patients who receive insufficient doses of antihypertensive agents or who are poorly adherent to multidrug treatment regimens often fail to achieve adequate blood pressure (BP) control. The aim of this study was to determine the efficacy of an angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) combination tablet containing a regular dose of irbesartan (100 mg) and a high dose of amlodipine (10 mg) with regard to lowering BP and other risk factors for cardiovascular disease.

METHODS

We retrospectively evaluated data from 68 patients with essential hypertension whose treatment regimen was changed either from combination treatment with an independent ARB and a low-dose or regular-dose CCB or from a combination tablet of ARB and a low-dose or regular-dose CCB to a combination tablet containing amlodipine 10 mg and irbesartan 100 mg, because of incomplete BP control. Previous treatments did not include irbesartan as the ARB.

RESULTS

The combination tablet decreased systolic and diastolic BP. In addition, it significantly decreased serum uric acid, low-density lipoprotein cholesterol, and increased high-density lipoprotein cholesterol levels, independent of the BP-lowering effect. Treatment with the combination tablet did not affect serum triglycerides, plasma glucose, glycated hemoglobin, serum potassium or creatinine levels, or the urinary albumin excretion rate.

CONCLUSION

The combination tablet containing amlodipine 10 mg and irbesartan 100 mg had a greater BP-lowering effect than an ARB and a low-dose or regular-dose CCB. In addition, the combination tablet had more favorable effects on serum uric acid, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol levels in patients with hypertension.

Для цитирования: Yagi Shusuke, Takashima Akira, Mitsugi Minoru, Wada Toshihiro, Hotchi Junko, Aihara Ken-Ichi, Hara Tomoya, Ishida Masayoshi, Fukuda Daiju, Ise Takayuki, Yamaguchi Koji, Tobiume Takeshi, Iwase Takashi, Yamada Hirotsugu, Soeki Takeshi, Wakatsuki Tetsuzo, Shimabukuro Michio, Akaike Masashi, Sata Masataka. Effect of combination tablets containing amlodipine 10 mg and irbesartan 100 mg on blood pressure and cardiovascular risk factors in patients with hypertension.. Therapeutics and clinical risk management. 2015. DOI: 10.2147/tcrm.s72299.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.